Navigate / EASA

AMC2 MED.B.090 Oncology

ED Decision 2019/002/R

(a)     Applicants who have been diagnosed with a malignant disease may be considered for a fit assessment provided that:

(1)     after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety;

(2)     time appropriate to the type of tumour and primary treatment has elapsed;

(3)     the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low;

(4)     there is no evidence of short or long-term sequelae from treatment that may jeopardise flight safety;

(5)     arrangements for an oncological follow-up have been made for an appropriate period of time.

(b)     Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit.

(c)      Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is a regular follow-up.